Japan is the second major market where Kisunla has received approval Kisunla was first approved in the United States in July 2024 INDIANAPOLIS , Sept. 24, 2024 /PRNewswire/ -- The Ministry of Health, Labour and Welfare Japan has approved KisunlaTM (donanemab-azbt, 350 mg/20 mL every four weeks injection for IV infusion), Eli Lilly and Company's (NYSE: LLY ) Alzheimer's treatment for adults with early symptomatic Alzheimer's disease (AD), which includes people with mild cognitive impairment (MCI) as well as people with the mild dementia stage of AD, with confirmed amyloid pathology. Japan is the second major market in which Kisunla has been approved for use.
In Japan , by 2030, the number of patients with dementia is estimated to be more than 5 million 1 , and AD is the most common cause of dementia, accounting for more than 67% of cases 2 . The number of AD patients is expected to increase significantly compared with other dementias. 3 "Lilly scientists have been dedicated to research in Alzheimer's disease for more than 35 years, and this news is testament to their ingenuity, perseverance, and commitment to helping people with this disease," said Ilya Yuffa , executive vice president and president of Lilly International, Eli Lilly and Company.
"Kisunla demonstrated very meaningful results for people with early symptomatic Alzheimer's disease by significantly slowing cognitive and functional decline in our TRAILBLAZER-ALZ 2 study, which included participants from Japan . Peop.
